{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:50:24Z","timestamp":1786549824122,"version":"build-2736575974"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"8127","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2026,8,13]]},"DOI":"10.1038\/s41586-026-10773-4","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:02:18Z","timestamp":1786546938000},"page":"E5-E6","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reply to: Pre-clinical data interpretation requires clinical context"],"prefix":"10.1038","volume":"656","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3056-7991","authenticated-orcid":false,"given":"Sean P.","family":"Pitroda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5643-8939","authenticated-orcid":false,"given":"Ralph R.","family":"Weichselbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"10773_CR1","doi-asserted-by":"publisher","unstructured":"Muirhead, R. et al. Pre-clinical data interpretation requires clinical context. Nature https:\/\/doi.org\/10.1038\/s41586-026-10774-3 (2026).","DOI":"10.1038\/s41586-026-10774-3"},{"key":"10773_CR2","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/s41586-025-08994-0","volume":"643","author":"A Piffk\u00f3","year":"2025","unstructured":"Piffk\u00f3, A. et al. Radiation-induced amphiregulin drives tumour metastasis. Nature 643, 810\u2013819 (2025).","journal-title":"Nature"},{"key":"10773_CR3","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","volume":"393","author":"DA Palma","year":"2019","unstructured":"Palma, D. A. et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 393, 2051\u20132058 (2019).","journal-title":"Lancet"},{"key":"10773_CR4","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0140-6736(23)01857-3","volume":"403","author":"CJ Tsai","year":"2024","unstructured":"Tsai, C. J. et al. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study. Lancet 403, 171\u2013182 (2024).","journal-title":"Lancet"},{"key":"10773_CR5","doi-asserted-by":"publisher","first-page":"8506","DOI":"10.1200\/JCO.2024.42.16_suppl.8506","volume":"42","author":"P Iyengar","year":"2024","unstructured":"Iyengar, P. et al. NRG-LU002: randomized phase II\/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC). J. Clin. Oncol. 42, 8506\u20138506 (2024).","journal-title":"J. Clin. Oncol."},{"key":"10773_CR6","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1200\/JCO.2022.40.16_suppl.1007","volume":"40","author":"SJ Chmura","year":"2022","unstructured":"Chmura, S. J. et al. NRG-BR002: a phase IIR\/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and\/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557). J. Clin. Oncol. 40, 1007\u20131007 (2022).","journal-title":"J. Clin. Oncol."},{"key":"10773_CR7","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1001\/jamaoncol.2018.6993","volume":"5","author":"DA Palma","year":"2019","unstructured":"Palma, D. A. et al. Measuring the integration of stereotactic ablative radiotherapy plus surgery for early-stage non-small cell lung cancer: a phase 2 clinical trial. JAMA Oncol. 5, 681\u2013688 (2019).","journal-title":"JAMA Oncol."},{"key":"10773_CR8","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1200\/JCO.20.00818","volume":"38","author":"DA Palma","year":"2020","unstructured":"Palma, D. A. et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J. Clin. Oncol. 38, 2830\u20132838 (2020).","journal-title":"J. Clin. Oncol."},{"key":"10773_CR9","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/nm0696-689","volume":"2","author":"MS O\u2019Reilly","year":"1996","unstructured":"O\u2019Reilly, M. S., Holmgren, L., Chen, C. & Folkman, J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med. 2, 689\u2013692 (1996).","journal-title":"Nat. Med."},{"key":"10773_CR10","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan3464","volume":"10","author":"JA Krall","year":"2018","unstructured":"Krall, J. A. et al. The systemic response to surgery triggers the outgrowth of distant immune-controlled tumors in mouse models of dormancy. Sci. Transl. Med. 10, eaan3464 (2018).","journal-title":"Sci. Transl. Med."},{"key":"10773_CR11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2515009122","volume":"122","author":"J Zhang","year":"2025","unstructured":"Zhang, J. et al. Inflammation awakens dormant cancer cells by modulating the epithelial-mesenchymal phenotypic state. Proc. Natl Acad. Sci. USA 122, e2515009122 (2025).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"10773_CR12","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/j.ccell.2025.06.007","volume":"43","author":"D He","year":"2025","unstructured":"He, D. et al. Chemotherapy awakens dormant cancer cells in lung by inducing neutrophil extracellular traps. Cancer Cell 43, 1622\u20131636.e7 (2025).","journal-title":"Cancer Cell"},{"key":"10773_CR13","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/s41586-025-09332-0","volume":"645","author":"SB Chia","year":"2025","unstructured":"Chia, S. B. et al. Respiratory viral infections awaken metastatic breast cancer cells in lungs. Nature 645, 496\u2013506 (2025).","journal-title":"Nature"},{"key":"10773_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","volume":"13","author":"S Hellmann","year":"1995","unstructured":"Hellmann, S. & Weichselbaum, R. R. Oligometastases. J. Clin. Oncol. 13, 8\u201310 (1995).","journal-title":"J. Clin. Oncol."},{"key":"10773_CR15","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1002\/cncr.26611","volume":"118","author":"JK Salama","year":"2012","unstructured":"Salama, J. K. et al. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer 118, 2962\u20132970 (2012).","journal-title":"Cancer"}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10773-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10773-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10773-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:02:19Z","timestamp":1786546939000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10773-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":15,"journal-issue":{"issue":"8127","published-print":{"date-parts":[[2026,8,13]]}},"alternative-id":["10773"],"URL":"https:\/\/doi.org\/10.1038\/s41586-026-10773-4","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"assertion":[{"value":"12 August 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.R.W. has stock and other ownership interests with Boost Therapeutics, Immvira, Reflexion Pharmaceuticals, Coordination Pharmaceuticals, Magi Therapeutics, Fuse Biotherapeutics and Oncosenescence. He has served in a consulting or advisory role for Aettis, Astrazeneca, Coordination Pharmaceuticals, Genus, Merck Serono, Nano proteagen, NKMax America and Shuttle Pharmaceuticals. He has received research grant funding from Varian and Regeneron, as well as NIH funding (R01CA262508 and U54 CA274291). He has received compensation including travel, accommodations or expense reimbursement from AstraZeneca, Boehringer Ingelhei and Merck Serono. S.P.P. has received research grant funding from the LUNGevity Foundation, Cancer Research Foundation, Falk Medical Research Trust and American Lung Association. R.R.W. and S.P.P. are co-founders of PersonaDx and have multiple patents pending. S.P.P. and R.R.W. have filed a patent on amphiregulin in the radiation response.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}